Eliminating roles for T-bet and IL-2 but revealing superior activation and proliferation as mechanisms underpinning dominance of regulatory T cells in tumors |
| |
Authors: | Emily J. Colbeck James P. Hindley Kathryn Smart Emma Jones Anja Bloom Hayley Bridgeman Rhoanne C. McPherson Darryl G. Turner Kristin Ladell David A. Price Richard A. O'Connor Stephen M. Anderton Andrew J. Godkin Awen M. Gallimore |
| |
Affiliation: | 1. Institute of Infection Immunity and Biochemistry, Cardiff University School of Medicine, Cardiff, UK;2. MRC Centre for Inflammation Research, Centre for Multiple Sclerosis Research and Centre for Immunity Infection and Evolution, University of Edinburgh, Edinburgh, UK |
| |
Abstract: | Foxp3+ regulatory T cells (Tregs) are often highly enriched within the tumor-infiltrating T cell pool. Using a well-characterised model of carcinogen-induced fibrosarcomas we show that the enriched tumor-infiltrating Treg population comprises largely of CXCR3+ T-bet+ ‘TH1-like’ Tregs which are thymus-derived Helios+ cells. Whilst IL-2 maintains homeostatic ratios of Tregs in lymphoid organs, we found that the perturbation in Treg frequencies in tumors is IL-2 independent. Moreover, we show that the TH1 phenotype of tumor-infiltrating Tregs is dispensable for their ability to influence tumor progression. We did however find that unlike Tconvs, the majority of intra-tumoral Tregs express the activation markers CD69, CD25, ICOS, CD103 and CTLA4 and are significantly more proliferative than Tconvs. Moreover, we have found that CD69+ Tregs are more suppressive than their CD69− counterparts. Collectively, these data indicate superior activation of Tregs in the tumor microenvironment, promoting their suppressive ability and selective proliferation at this site. |
| |
Keywords: | Treg Cancer proliferation T-bet CD69 Immunology Section Immunity Immune response |
|
|